Epistaxis er den mest almindelig behandlingsrelaterede bivirkning inden for blødning, hvor ca. halvdelen af patienterne med solide tumorer oplever blødning.
Epistaxis was the most common treatment-related haemorrhagic adverse event, having been reported for approximately half of the patients with solid tumours who experienced haemorrhagic events.